[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-knee-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-knee-pain":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,42,66,97,122,149,173,203,234,266,296,325,351,372,398],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100599090","effects-of-photobiomodulation-on-inflammation-and-chronic-pain-in-knee-osteoarthritis-epic-ko-100599090",false,"NCT07079969","Effects of Photobiomodulation on Inflammation and Chronic Pain in Knee Osteoarthritis (EPIC-KO)","Effects of Photobiomodulation on Inflammation and Chronic Pain in Knee Osteoarthritis","EPIC-KO","Inclusion Criteria:\n\n* Clinically confirmed knee osteoarthritis (OA) based on the American College of Rheumatology (ACR) criteria with symptomatic pain for ≥ 3 months\n* Average knee-pain intensity ≥ 30\u002F100 on both the Daily Symptom Diary (DSD) run-in and CATI\n* Age ≥ 50 years\n* Ability to give informed consent, attend visits, and complete ≥ 4 of 7 DSD entries pre-randomization\n* Capacity to perform all study tasks (Timed Up-and-Go, knee OA assessments, blood draw, questionnaires, etc)\n\nExclusion Criteria:\n\nSystemic and Rheumatic Disease\n\n* Active systemic rheumatic condition (e.g., rheumatoid arthritis, systemic lupus erythematosus)\n* Fibromyalgia with pain outside the knee that is equal to or worse than knee pain\n\nMusculoskeletal History\n\n* Clinically significant surgery on the index knee (e.g., arthroplasty, osteotomy)\n* Knee surgery within the past 6 weeks\n* Intra-articular injection to the index knee within the past 14 days\n\nMedication Use\n\n* Daily opioid therapy\n* Hypersensitivity to PBM\n* Migraine triggered by light\n* Open wounds, skin infections, eczema, burns, or other dermatologic conditions at or near the treatment application site.\n* New prescription or OTC analgesic, non-pharmacologic pain therapy, chemotherapy, or radiation therapy initiated ≤ 30 days before screening\n\nCardiovascular Safety\n\n* Uncontrolled hypertension (SBP \\> 150 mmHg or DBP \\> 95 mmHg)\n* Unstable or activity-limiting cardiovascular or peripheral arterial disease\n\nNeurological and Psychiatric Conditions\n\n* Diagnosed neurological disorder (e.g., Parkinson's disease, multiple sclerosis, epilepsy)\n* History or evidence of stroke or moderate-severe traumatic brain injury\n* Serious psychiatric illness requiring hospitalization within the past 12 months\n* Active suicidal ideation\n* Current substance-use disorder or past hospitalization for substance-use treatment\n\nDermatologic Conditions\n\n* Compromised skin integrity at or near the treatment site (e.g., open wounds, active rash, dermatitis, burns, ulcers, eczema, infection) interfering with topical treatment or PBM\n\nOther Metabolic Conditions\n\n* Uncontrolled diabetes\n* Diabetes-related complications (e.g., peripheral neuropathy, severe nephropathy, chronic ulcers at treatment site)\n\nOther Pain Conditions\n\n* Chronic pain at another body site more severe than knee pain\n\nGeneral Health and Cognition\n\n* Pregnancy or lactation\n* Cognitive impairment that precludes informed consent or task participation","ALL","50 Years","99 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to determine analgesic and anti-inflammatory effects of dual-wavelength PBM in people with symptomatic knee OA.",[28],"Chronic Knee Pain","NOT_YET_RECRUITING","2026-05-22",{"date":32,"type":33},"2026-05-27","ACTUAL",{"date":35,"type":22},"2026-07",{"date":37,"type":22},"2027-07",{"name":39,"class":40},"University of Florida","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":41},"100516466","peripheral-nerve-stimulation-of-genicular-nerves-versus-conventional-therapy-with-intra-articular-steroid-injection-for-chronic-knee-pain-a-prospective-randomized-pilot-study-100516466","NCT06004882","Peripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study","Inclusion Criteria:\n\n* Patients diagnosed with chronic knee pain (baseline pain score \\>=4), seen at Pain Management Center at MD Anderson Cancer Center; if patient has bilateral knee pain, the side with the more severe knee pain will be treated first and counted towards the primary and secondary endpoints\n* Patients between ages 18-85 years old\n* Patient signed informed consent\n\nExclusion Criteria:\n\n* Patients with cognitive dysfunction or without capacity to consent\n* Patient with recent history (\\\u003C6 months) of drug or alcohol abuse\n* Patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection\n* Patients with allergies to local anesthesia, steroids, or adhesives\n* Patients who are on opioids for reasons other than knee pain","18 Years",{"count":50,"type":22},45,[25],"To compare the effects of the following types of therapy on knee range of motion when given to patients with chronic knee pain:\n\n* A standard steroid injection\n* Peripheral nerve stimulation (PNS) therapy in combination with a standard steroid injection\n* PNS therapy in combination with a placebo injection\n\nSteroid injections are given directly into the knee joints and are considered to be the standard therapy for chronic knee pain. In this study, the injection will be made of the steroid drugs triamcinolone and bupivacaine.",[54,55,28],"Peripheral Nerve Stimulation","Genicular Nerves","RECRUITING","2026-02-27",{"date":59,"type":33},"2026-03-03",{"date":61,"type":33},"2023-08-10",{"date":63,"type":22},"2027-01-31",{"name":65,"class":40},"M.D. Anderson Cancer Center",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100564259","early-phase-1-treating-chronic-pain-of-peripheral-nerve-origin-with-the-novel-noninvasive-hypersound-neuromodulation-system-100564259","NCT06626854","Treating Chronic Pain of Peripheral Nerve Origin With the Novel Noninvasive Hypersound Neuromodulation System","Prospective, Randomized Study to Assess the Safety and Efficacy of the Novel Noninvasive Hypersound Neuromodulation System in the Treatment of Patients With Chronic Pain of Peripheral Nerve Origin, Including Neuropathy, Sciatica, and Joint Pain","Inclusion Criteria:\n\n* Pain greater than mid-range using standardized pain inventory (SPI).\n* No medication for pain both over-the-counter and by prescription for 24 hours prior to treatment.\n* Body mass index (BMI) to be calculated for all participants with limitation for any BMI that is lower than normal. (Target is normal, overweight or obese).\n* Age greater than 18.\n\nExclusion Criteria:\n\n* Existing Peripheral Nerve Stimulator Implant in the lower extremities","75 Years",{"count":75,"type":22},5,[77],"EARLY_PHASE1","First, the subject will undergo screening and provide informed consent. Baseline measurements are then taken. The subject remains seated with back support throughout the session. The technician verifies and marks the knee for treatment and wraps an antenna applicator strap around the lower leg near the knee. The device is turned on in test mode to confirm the therapy location, with the subject identifying when they feel a sensation over their pain area. The power threshold for this sensation is recorded. The therapy, which lasts 15 minutes, is delivered at 90% of this threshold to ensure the subject does not feel it. After therapy, post-treatment measurements are taken.",[28,80,81],"Chronic Knee Osteoarthritis","Post Surgical Neuropathic Pain",[83,84,85,86],"rfPNS","Hypersound","Neuroharmonix","Noninvasive PNS","2026-02-19",{"date":89,"type":33},"2026-02-23",{"date":91,"type":22},"2026-06-10",{"date":93,"type":22},"2026-12-10",{"name":95,"class":96},"Hypersound Medical Inc","INDUSTRY",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":41},"100616689","individual-differences-in-gait-and-osteoarthritis-pain-100616689","NCT07308873","Individual Differences in Gait and Osteoarthritis Pain","INDIGO","Inclusion Criteria:\n\n* Knee pain for greater than 6 months.\n* Moderate-to-severe knee pain (\\>3\u002F10) due to osteoarthritis, as defined by American College of Rheumatology and EULAR diagnostic criteria, on \\>50% of days in the past month.\n* KL grade 2-4 indicating significant degenerative changes on knee X-ray.\n* 45-80 years old\n\nExclusion Criteria:\n\n* Inflammatory arthritis (e.g. rheumatoid arthritis).\n* More intense pain due to another chronic pain syndrome (e.g. fibromyalgia, hip osteoarthritis)\n* Significant pain or weakness in the lower extremities due to a neurological condition (e.g. lumbar radiculopathy, paresis due to stroke)\n* Acute pain that is more intense than knee osteoarthritis pain\n* Current routine use of more than 15 mg oral morphine equivalents per day (use of \\\u003C15 mg OME does not exclude the participant).\n* Recent new medication, exercise, behavioral, or complementary and integrative treatment started in the last month. Stable use of these treatments for greater than 1 month does not exclude the participant.\n* Recent intra-articular injection of steroid or other agent (greater than 1 month does not exclude the participant)\n* Recent knee radiofrequency ablation (greater than 3 months does not exclude the participant)\n* Recent knee arthroscopic surgery (greater than 3 months does not exclude the participant)\n* History of knee replacement or open knee surgery on the index knee, defined as the more painful knee on average over the last month.\n* Inability to walk or climb stairs without significant assistance (e.g. a one-person assist, use a wheel chair; however, the use of a cane does not exclude the participant).\n* Inability to participate in study procedures (e.g. cognitive impairment limiting ability to understand directions, inability to understand and read English)\n* Uncontrolled or unstable medical disorder preventing participation in study procedures\n* History of brain surgery\n* Tattoos on sensory testing sites\n* Pregnancy\n* Breastfeeding\n* Inability to under knee MRI scan due to incompatible devices or foreign bodies.","45 Years","80 Years",{"count":107,"type":22},300,"OBSERVATIONAL","The goal of this observational study is to look at inter-individual differences in knee osteoarthritis (OA) walking pain and performance. The main questions this study aims to answer are:\n\nWhy do some people with knee osteoarthritis have more severe disabling pain than others, even though the degenerative changes in their knees are similar?\n\nWhat are the factors that contribute to walking pain in people with knee osteoarthritis?\n\nParticipants will complete surveys, perform physical function tasks, get a knee X-ray and MRI, undergo non-invasive brain imaging, and undergo sensory testing.",[111,112,28],"Knee Osteoarthritis (OA)","Chronic Pain","2026-01-27",{"date":115,"type":33},"2026-01-29",{"date":117,"type":33},"2026-01-07",{"date":119,"type":22},"2030-08-01",{"name":121,"class":40},"University of Pittsburgh",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":41},"100606699","neurolysis-for-the-treatment-of-medial-chronic-knee-pain-due-to-osteoarthritis-100606699","NCT07178951","Neurolysis for the Treatment of Medial Chronic Knee Pain Due to Osteoarthritis","Safety and Feasibility of the Neurolyser XR Device for the Treatment of Predominantly Medial Chronic Knee Pain Due to Osteoarthritis","Inclusion Criteria:\n\n1. Moderate to severe, predominantly medial chronic knee pain\n2. Age adult \\>18 years old\n3. WOMAC Score of 30 or higher\n4. NRS\\>6 with ambulation\n5. Radiological confirmation of knee osteoarthritis (Kellgren-Lawrence Scale: 2-4)\n6. Participants in whom the measured skin to bone depth is 2-6 cm using imaging ultrasound and ultrasound gel pad in the upper medial and lower medial joint capsule targets.\n\nExclusion Criteria:\n\n1. Individuals meeting any of the following criteria are not eligible for participation in this study:\n2. Individuals after any surgery associated with altered integrity of bone structure\n3. Individuals with severe pain in the second knee\n4. Individuals unable to understand and complete the research questionnaires in the official language\n5. Individuals presenting with any severe medical condition preventing the participant from safely and effectively being treated in the study or reporting study outcomes, per PI decision\n6. Individuals with extensive scarring of the skin and tissue overlying the treatment area\n7. Individuals enrolled in or planned to be enrolled in another clinical trial during the duration of this research project\n8. Individuals with active inflammatory (e.g., rheumatoid) arthritis\n9. Individuals with concomitant mental health disorders, excluding compensated mood disorders\n10. Individuals with altered perception and processing of pain: Average NRS \\> 9, PCS\\>30, SSS-8 \\> 11, CSI\\>40 \\[46\\], \\[47\\], \\[48\\]\n11. Individuals with a first-degree family member already enrolled in this study\n12. Individuals who are scheduled for any interventional\u002Fsurgical procedure within 3 months from the screening date, excluding trivial surgeries (e.g., cataract, skin tumors)\n13. Inability to attend follow-up visits and physiotherapy due to travel distance or other restrictions\n14. Symptomatic multifocal nociplastic chronic pain (e.g., fibromyalgia, generalized osteoarthritis) or any other chronic pain condition that could influence symptoms.\n15. Participants who have undergone radiofrequency ablation of the genicular nerves in the planned treatment limb within the preceding 6 months.",{"count":130,"type":22},10,[25],"This study involves the use of sound waves to block pain signals caused by osteoarthritis of the knee. The sound waves are tightly focused on a specific area of the nerve. The sound waves cause a break in the nerve which carries pain signals. Sound waves transmit through the skin so there is no need for needles. The procedure takes approximately one hour. The device has been approved in Health Canada and Europe for the treatment of lower back pain. This study is to evaluate the use of the same device for people in Canada who have knee pain related to osteoarthritis.",[134,135,28],"Osteoarthritis (OA) of the Knee","Knee Pain Arthritis",[137,138,139,140],"osteoarthritis","knee pain","focused ultrasound","nerve ablation","2026-01-05",{"date":117,"type":33},{"date":144,"type":22},"2026-01",{"date":146,"type":22},"2026-12",{"name":148,"class":96},"FUSMobile Inc.",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":41},"100509972","radiofrequency-ablation-for-the-treatment-of-post-knee-arthroplasty-chronic-pain-100509972","NCT05920382","Radiofrequency Ablation for the Treatment of Post-knee Arthroplasty Chronic Pain.","Radiofrequency Ablation for the Treatment of Post-knee Arthroplasty Chronic Pain. A Randomized Double-blind Study. A Novel Approach.","CSAPG-37","Inclusion Criteria:\n\n* Individuals who have undergone knee arthroplasty.\n* Chronic knee pain post-knee arthroplasty for at least 6 months after the procedure and less than 5 years.\n* Pain intensity on the numerical visual scale ≥ 5 out of 10 points.\n* Stable pain for the last 30 days.\n* The knee is the location with the highest intensity of pain, in the case of patients with multiple joint pains.\n\nExclusion Criteria:\n\n* Acute knee pain.\n* Psychiatric illness or dementia that may interfere with or hinder study assessments.\n* Diagnosis of fibromyalgia, chronic fatigue syndrome, or central sensitization syndrome.\n* Knee infiltration with corticosteroids in the past 30 days.\n* Changes in oral analgesic medication in the past 30 days.",{"count":158,"type":22},86,[25],"Knee osteoarthritis pain is one of the conditions commonly seen in general and specialized medicine. Knee arthroplasty is one of the most successful orthopedic surgeries for the treatment of this disease, significantly improving pain, disability, and the overall quality of life for patients who undergo it. However, there is a subgroup of individuals in whom the pain persists or even worsens. Radiofrequency has been introduced over 10 years ago as a neuroablative technique targeting the genicular nerves, which innervate the sensory terminals of the knee joint, for the treatment of chronic pain in that region before or after arthroplasty. However, the results have not been entirely consistent. Recent anatomical studies have demonstrated the presence of other sensory terminal branches of the femoral nerve, such as the infrapatellar branch of the saphenous nerve, medial vastus nerve, intermediate vastus nerve, and lateral vastus nerve, which could be useful targets for the treatment of post-knee arthroplasty pain. To date, no studies have been conducted to address post-knee arthroplasty pain through the application of thermal radiofrequency on the sensory branches of the knee from the femoral nerve (infrapatellar branch of the saphenous nerve, medial vastus nerve, intermediate vastus nerve, lateral vastus nerve). Therefore, The investigators aim to conduct a randomized double-blind clinical trial where The investigators will apply thermal radiofrequency on the sensory terminal branches of the femoral nerve in the knee, based on recent anatomical studies. The objective of the study is to determine if radiofrequency ablation of sensory nerves in the knee improves pain and disability in patients with post-knee arthroplasty chronic pain at the L'Alt Penedés-Garraf Health Consortium. Method: This is a randomized double-blind clinical trial with two arms. Two groups will be used, where one group will receive thermal radiofrequency of sensory nerves in the knee, and the other group will receive a placebo treatment. The hypothesis The investigators propose is that radiofrequency ablation will alleviate at least 50% of baseline pain and disability in at least 50% of the patients.",[162,163,28],"Chronic Post-surgical Pain","Chronic Post Operative Pain","2025-12-02",{"date":166,"type":33},"2025-12-09",{"date":168,"type":33},"2023-09-25",{"date":170,"type":22},"2027-12-01",{"name":172,"class":40},"Consorci Sanitari de l'Alt Penedès i Garraf",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":181,"sex":17,"minAge":182,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":41},"100614596","investigating-the-role-of-central-pain-hypersensitivity-in-skeletal-muscle-neural-drive-100614596","NCT07281651","Investigating the Role of Central Pain Hypersensitivity in Skeletal Muscle Neural Drive","Investigating the Role of Central Pain Hypersensitivity in Skeletal Muscle Neural Drive, in People With Knee Pain, and in People With Fibromyalgia Syndrome (Pain-Neural Drive)","Pain-Drive","Inclusion Criteria:\n\nKnee pain group\n\n* History of knee pain with an intensity level of 4 out of 10 or greater (where 0 is no pain and 10 is the worst pain imaginable) for most days in the past 3 months\n\nFibromyalgia group\n\n* Fibromyalgia diagnosis (participant self-reporting a previous diagnosis by a clinician)\n* Pain with an intensity level of 4 out of 10 or greater (where 0 is no pain and 10 is the worst pain imaginable) for most days in the past 3 months\n\nControl group\n\n\\- Pain free individuals without known osteoarthritis\n\nExclusion Criteria:\n\n* BMI\\>35\n* Body weight of 250kg or higher\n* Pregnancy (women)\n* Inability to give consent\n* Inability to meet the requirements of clinical assessment\n* Performed strenuous physical exercise in the past 24 hours prior to testing\n* Consumed alcohol on day of testing\n* Consumed caffeine on day of testing",true,"40 Years",{"count":184,"type":22},135,"Background: pain lasting for 12 weeks or beyond, which is often referred to as chronic pain, is common for people living with musculoskeletal conditions (e.g. arthritis, low back pain and fibromyalgia). Pain is often not directly related to the degree of muscle or joint damage. Adaptations of the central nervous system (brain, spinal cord and nerves) often occur in chronic musculoskeletal conditions and can influence how we feel pain (central pain hypersensitivity). Pain can impact on muscle activity and movement. Muscle activity is also governed by nerve signals from the central nervous system (neural drive).\n\nThe goal of this cross-sectional observational study is to investigate whether chronic musculoskeletal pain is associated with altered nerve signalling (neural drive) to skeletal muscles in adults 40 years or over with chronic knee pain, fibromyalgia and healthy pain free volunteers.\n\nThe main questions it aims to answer are:-\n\n* Is central pain hypersensitivity associated with altered nerve signalling to skeletal muscles in adults 40 years or over with chronic pain (knee pain and for fibromyalgia) as well as healthy volunteers?\n* Is altered nerve signalling to skeletal muscles associated with physical function and disability?\n\nParticipants will be asked to:-\n\n* Have sensory testing to determine how they feel pain\n* Complete static leg and arm muscle contractions with electrodes on the skin to measure muscle electrical activity\n* Complete questionnaires\n* Perform a short set of mobility tasks including walking, rising from a chair and balancing.",[28,187],"Fibromyalgia",[112,189,187,190,191,192,193],"Musculoskeletal Conditions","Muscle Function","Physical Functioning","Disability","Central Aspects of Pain","2025-12-01",{"date":196,"type":33},"2025-12-15",{"date":198,"type":33},"2025-11-24",{"date":200,"type":22},"2026-09",{"name":202,"class":40},"University of Nottingham",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":210,"enrollmentInfo":211,"targetDuration":4,"studyType":23,"phases":213,"briefSummary":214,"conditions":215,"keywords":219,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":233},"100606704","evaluating-the-auricular-point-acupressure-self-management-program-for-chronic-musculoskeletal-pain-among-rural-populations-100606704","NCT07179016","Evaluating the Auricular Point Acupressure-Self Management Program for Chronic Musculoskeletal Pain Among Rural Populations","A Pragmatic, Randomized Controlled Trial of a Auricular Point Acupressure - Self-Management (APA-SM) Program for Chronic Musculoskeletal Pain Among Rural Populations.","Inclusion Criteria:\n\n* Receive any pain management for CMP (neck, back, shoulder, hands, hips, knees, feet)\n* Have CMP ≥ 4 on a scale of 0-10 that has persisted for at least 3 months or has resulted in pain on at least half the days in the past 6 months\n\nExclusion Criteria:\n\n* Severe ear skin disorder (Diagnosed with conditions e.g., eczema, lupus with skin involvement) which often require medical intervention and severe allergy to tape\n* Inability or unwillingness to provide informed consent\n* Use of some type of hearing aid where size may obstruct seed placement\n* Not living in rural area","85 Years",{"count":212,"type":22},693,[25],"The investigators will test an Auricular Point Acupressure Self-Management (APA-SM) program integrated into rural primary and specialty care and rural communities for chronic musculoskeletal pain (CMP). To maximize self-management of pain, the investigators developed a smartphone app which will allow the participants to learn to self-administer APA. The investigators will have 3 arms (APA-SM self-guided with remote training, APA-SM with in-person training, and Education Control) with 231 participants per arm (total=693 for 3 arms). The investigators will evaluate the clinical effectiveness of our 4-week APA-SM intervention compared to control in primary outcomes (pain intensity, pain interference, activity), secondary outcomes (HEAL Clinical Pain Core common data elements), and analgesic use up to 6 months follow-up.",[216,217,28,218],"Chronic Pain (Back \u002F Neck)","Chronic Pain Management","Joint Pain",[112,220,221,222,223],"Rural population","Self-management","Chronic musculoskeletal pain","Auricular point acupressure","2025-09-24",{"date":226,"type":33},"2025-10-01",{"date":228,"type":33},"2025-09-11",{"date":230,"type":22},"2029-08-31",{"name":232,"class":40},"The University of Texas Health Science Center, Houston",3,{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":23,"phases":243,"briefSummary":244,"conditions":245,"keywords":248,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":265},"100598945","laterality-training-and-pain-drawings-100598945","NCT07078084","Laterality Training and Pain Drawings","Laterality Training and Pain Drawings: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of chronic shoulder or knee pain lasting more than 6 months\n* Able to read and understand English\n* Willing to provide written informed consent\n\nExclusion Criteria:\n\n* Visual impairments that would interfere with laterality training (e.g., blindness or significant difficulty with vision)\n* Previous participation in laterality (left\u002Fright discrimination) training\n* Unwilling or unable to participate in the study procedures",{"count":242,"type":22},60,[25],"The goal of this clinical trial is to learn if laterality training (a type of brain-based therapy) can help reduce pain and change how people with chronic musculoskeletal pain experience and describe their pain. The study will focus on adults with shoulder or knee pain lasting longer than 6 months.\n\nThe main questions it aims to answer are:\n\nDoes laterality training lead to a reduction in self-reported pain levels?\n\nDoes laterality training reduce the area of the body that participants indicate as painful in their pain drawings?\n\nDoes laterality training improve accuracy and speed in left\u002Fright judgment tasks?\n\nResearchers will compare participants who complete laterality training to those who complete a non-therapeutic cognitive task (a word puzzle) to see if laterality training changes pain drawings and improves pain outcomes.\n\nParticipants will:\n\nComplete a pre-intervention assessment including pain ratings, pain drawings, and a left\u002Fright judgment test\n\nBe randomly assigned to one of two groups:\n\nIntervention group: Complete 5 one-minute sessions of laterality training using a tablet-based app called Recognise™, identifying left or right hand\u002Ffoot images depending on the location of their pain\n\nControl group: Complete a 10-minute crossword puzzle activity (non-therapeutic)\n\nComplete the same assessments after the activity (pain ratings, pain drawings, left\u002Fright judgment test)\n\nThe study will take place at two outpatient physical therapy clinics. Participation involves a single session lasting approximately 30-45 minutes. There is no cost to participate, and no compensation is provided. Participation is voluntary, and all personal data will be kept confidential.\n\nThis research will help determine whether laterality training, a non-invasive brain-based technique, can reduce pain and improve quality of life in people with long-standing musculoskeletal pain.",[246,247,28],"Chronic Musculoskeletal Pain","Chronic Shoulder Pain",[222,249,250,251,252,253,254,255],"Shoulder pain","Knee pain","Laterality training","Left\u002Fright discrimination","Graded motor imagery","Pain neuroscience","Pain drawings","2025-07-12",{"date":258,"type":33},"2025-07-22",{"date":260,"type":22},"2025-08",{"date":262,"type":22},"2026-02",{"name":264,"class":40},"Hawaii Pacific University",2,{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":23,"phases":276,"briefSummary":279,"conditions":280,"keywords":282,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":294,"locationsCount":41},"100502018","phase-2-photobiomodulation-in-chronic-knee-pain-in-patients-who-are-in-prerehabilitation-for-bariatric-surgery-100502018","NCT05816798","Photobiomodulation in Chronic Knee Pain in Patients Who Are in PreRehabilitation for Bariatric Surgery","Photobiomodulation in Chronic Knee Pain in Patients Who Are in PreRehabilitation for Bariatric Surgery: Double Blind, Randomized, Controlled Placebo Clinical Trial","Inclusion Criteria:\n\n* Obese patients with indication for bariatric surgery performed in routine follow-up at the Gastric Surgery Outpatient Clinic of HC-UFG;\n* Patients with chronic pain (\\> 3 months) in the knees bilaterally. Patients will be asked in the initial evaluation if they feel pain located in the topography of the knees that has been compromising their functionality both in daily activities and at work, and that lasts for more than or equal to 3 months. This pain may be reported as continuous or intermittent;\n* Sign the Informed Consent Term approved by the HC-UFG Ethics Committee.\n\nExclusion Criteria:\n\n* \\- Loss of follow-up in the outpatient clinic of origin and in the Physiotherapy sector, even though the use of laser therapy was maintained according to the study protocol;\n* Any reported adverse effects from the use of FBM reported;\n* Patients in whom there are changes in the medications being used for chronic pain during the study protocol will be excluded from this study. Minimal changes in the dosages of medications already in use can be tolerated, as long as there are no changes in the type of medication, but only in the prescribed dose. These modifications throughout the study, if they occur, will be described.\n* Death\n* Withdrawal of the informed consent by the participant\n* If the patient, for any reason, is excluded from the indication of bariatric surgery\n* Emergence during the study of any of the non-inclusion criteria, like: .\n* Patients with other rheumatologic diseases and\u002For systemic inflammatory diseases (rheumatoid arthritis, Reiter's arthritis, ankylosing spondylitis, generalized polyarthritis) or previous musculoskeletal diseases in the knees;\n* Clinical manifestations or complaints of knee arthralgia related to diseases other than obesity.\n* Previous use in the last 90 days of treatment with the use of Phototherapy for the same or another indication;\n* Clinical signs of neuropathy, including radiculopathies and peripheral nerve injuries;\n* Pain in the lower limb, originating from the lumbar spine (lombosciatalgia)\n* Use of corticosteroids at an immunosuppressive dose (20mg daily of prednisone or equivalent for at least 14 days);\n* Infection or tumor at the site of therapy application;\n* Current chronic infections such as tuberculosis or chronic hepatitis treated or not.\n* Blood clotting disorders (including thrombosis) at the application site.\n* Diagnosis of fibromyalgia;\n* Serious psychiatric disorders that require psychiatric care;\n* Systemic injections and\u002For joint injections of corticosteroids or hyaluronic acid during the last 48 hours prior to the initial assessment of the study;\n* Psychoaffective disorder that compromises adherence to treatment;\n* Any history of sensitivity to light or phototherapies.","70 Years",{"count":275,"type":22},62,[277,278],"PHASE2","PHASE3","Chronic pain is a global public health problem, which intensifies even more in the obese population, reaching about 33% of these patients. Among the topography, chronic knee pain affects 80%, constituting an important cause of disability and decreased quality of life. In addition, in grade 3 obesity, also called morbid obesity, in which bariatric surgery is already indicated, knee pain makes it difficult or prevents participation in the pre-habilitation program that includes physical therapy through therapeutic exercises with the aim of reducing postoperative complications. In this sense, a double-blind, randomized, placebo-controlled clinical trial will be conducted with the objective of evaluating the effect of photobiomodulation (PBM) on pain and functionality of obese patients with chronic knee pain who are in a prehabilitation program for bariatric surgery, discussing its role as an analgesic therapy and modifier of peripheral and central sensitization mechanisms of the pain pathway. PBM is a safe treatment option, with no undesirable effects and low cost. The primary outcomes will be pain intensity, through visual analogue scale, and Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire, validated version for Portuguese - Brazil. Secondary outcomes will be pressure pain threshold and rolling pinch maneuver measured by digital algometer. Other exploratory outcomes will be 6-minute walk test, knee range of motion, SF-36 quality of life questionnaire. There will be 2 groups: an intervention group (photobiomodulation associated with standard physiotherapy treatment) and another placebo group (device turned off associated with the same standard physiotherapy treatment). The application sites will be knees and lumbar paravertebral 2 times a week for 12 weeks. The dosimetric standards will be 4J\u002Fpoint in the knees and 3J\u002Fpoint in the lumbar. The results obtained will be statistically analyzed and later published in a scientific journal.",[28,281],"Obesity, Morbid",[283,284,285,286,287],"Photobiomodulation","Chronic knee pain","Obesity Morbid","Central and periferic sensitivity","Nociception","2025-06-02",{"date":290,"type":33},"2025-06-06",{"date":292,"type":33},"2023-07-28",{"date":262,"type":22},{"name":295,"class":40},"University of Nove de Julho",{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":17,"minAge":303,"maxAge":210,"enrollmentInfo":304,"targetDuration":4,"studyType":23,"phases":305,"briefSummary":306,"conditions":307,"keywords":309,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":41},"100570647","the-effect-of-intermittent-theta-burst-stimulation-on-brain-characteristics-pain-intensity-and-cognitive-functions-in-older-people-with-chronic-musculoskeletal-pain-100570647","NCT06709963","The Effect of Intermittent Theta Burst Stimulation on Brain Characteristics, Pain Intensity, and Cognitive Functions in Older People with Chronic Musculoskeletal Pain.","The Effect of Intermittent Theta Burst Stimulation on Brain Characteristics, Pain Intensity, and Cognitive Functions in Older People with Chronic Musculoskeletal Pain: a Double-blinded, Randomized, Sham-controlled, Mixed-methods, Pilot Trial with a Six-month Post-treatment Follow-up.","Inclusion Criteria:\n\n* have normal cognitive function (Hong Kong Montreal Cognitive Assessment ≥ 26)\n* be right-handed\n* be able to speak Cantonese\n* chronic nonspecific low back pain, or having both chronic nonspecific low back pain and chronic knee pain that has lasted for at least 3 months\n* an average pain intensity of ≥ 5 out of 10 on an 11-point numerical rating scale in the last 7 days, where 0 means \"no pain\" and 10 means \"worst pain imaginable\"\n* having pain at least half of the days in the past 4 weeks.\n* have at least 6 years of formal education and know how to read and write Chinese\n* agree to sign an informed consent and complete the experiment tests\n* be able to communicate via email or text message, as several study measures will be collected electronically\n\nExclusion Criteria:\n\n* inability to ambulate without assistance from another person (canes or walkers will be allowed);\n* having specific causes of chronic nonspecific low back pain, or having both chronic nonspecific low back pain and chronic knee pain (e.g., spinal stenosis, lumbar disc herniation, spondylolisthesis, recent vertebral fracture, spinal infection);\n* having other concurrent musculoskeletal conditions at other body parts (e.g., fibromyalgia, or neck pain)\n* self-reported history of lumbar or lower extremity surgery\n* self-reported history of neurological or psychiatric disorders (e.g., stroke, brain surgery, head trauma; schizophrenia, multiple personality disorder, dissociative identity disorder, stroke) or self-reported cancer history\n* self-reported specific inflammatory disorder: rheumatoid arthritis, rheumatica, scleroderma, lupus, or polymyositis\n* unexplained, unintended weight loss of 20 lbs or more in the past year\n* cauda equina syndrome\n* uncorrected visual deficit\n* drug or alcohol addiction\n* taken alcohol, opioids or benzodiazepines medicines 24 hours before the experiment\n* claustrophobia\n* contraindications for undergoing the magnetic resonance imaging (MRI) examination based on the MRI safety screening form of University Research Facility in Behavioral and Systems Neuroscience (UBSN) at The Hong Kong Polytechnic University (PolyU)","60 Years",{"count":21,"type":22},[25],"The goal of this clinical trial is to explore the effects of accelerated intermittent Theta Burst Stimulation (iTBS) on pain relief and cognitive function in older adults with chronic musculoskeletal pain. It will also utilize magnetic resonance imaging to illustrate the neurophysiological mechanisms underlying the role of iTBS in improving various outcome indicators in this population.\n\nThe main questions it aims to answer are:\n\n1. Is left dorsolateral prefrontal cortex stimulation using accelerated iTBS effective for older adults with chronic musculoskeletal pain?\n2. What are the neurophysiological mechanisms underlying the role of iTBS in improving various outcome indicators in older adults with chronic musculoskeletal pain?\n\nParticipants will:\n\n1. Receive 1,200 stimuli during a single-session iTBS, totaling 14 days.\n2. Undergo MRI scanning before, immediately after treatment, cognitive and pain-related tests before, immediately after treatment, and during follow-up.",[308,28,246],"Chronic Non-Specific Low Back Pain",[310,311,312,284,313,314,315],"Chronic non-specific low back pain","rTMS","Sham","DLPFC","chronic musculoskeletal pain","iTBS","2025-01-14",{"date":318,"type":33},"2025-01-15",{"date":320,"type":33},"2024-09-20",{"date":322,"type":22},"2026-12-31",{"name":324,"class":40},"The Hong Kong Polytechnic University",{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":17,"minAge":303,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":23,"phases":335,"briefSummary":336,"conditions":337,"keywords":338,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":4},"100570499","self-management-and-exercise-programme-using-mobile-instant-messaging-application-for-older-adults-living-with-chronic-knee-pain-100570499","NCT06708039","Self-Management and Exercise Programme Using Mobile Instant Messaging Application for Older Adults Living with Chronic Knee Pain","Self-Management and Exercise Programme Using Mobile Instant Messaging Application for Older Adults Living with Chronic Knee Pain.","SMEP","Inclusion Criteria:\n\n* Self-report of having the pain for more than 6 months.\n* Able to meet programme requirement - screening via KNEST and PAR-Q.\n* Owning a smartphone, tablet, or computer with an internet connection and WhatsApp application; and being able to use the device without assistance.\n* Independently mobile either with or without a walking aid.\n* Able to communicate in Malay.\n* Able to read and write in Malay.\n\nExclusion Criteria:\n\n* Knee replacement \u002F lower limb arthroplasty.\n* Intraarticular injections within the past six months.\n* Significant musculoskeletal issues (e.g. inflammatory arthritis, connective tissue diseases, fibromyalgia, severe osteoporosis, peripheral neuropathy, or gout).\n* Unstable medical or psychiatric conditions.\n* Severe cognitive, auditory or visual impairment.",{"count":334,"type":22},82,[25],"The goal of this Cluster Randomised, controlled trial (CRT, with two parallel groups pre- and post-test design) is to evaluate the potential effects of the self-management and exercise programme (SMEP) for older adults living with chronic knee pain which is delivered using mobile instant messaging application. The main questions it aims to answer are:\n\n1. Are there any change in pain, physical function, mental well-being, the risk of fall, health belief and self-efficacy and quality of life after the intervention is carried out at week 5?\n2. Are there any significance difference in pain, physical function, mental well-being, the risk of fall, health belief and self-efficacy and quality of life between the experimental and control group at baseline and week 5.\n3. What are the factors related to the adherence to programme within 5 weeks it is delivered.\n4. What are the factors that facilitates or inhibits the implementation process of the programme\n\nSelected clusters will be randomized into either experimental or control group. The experimental group will receive the self-management and exercise programme, which will be delivered using mobile messaging application, twice per week for five weeks. In addition, the experimental group will also continue their Elderly Day Care Centre routine activities. On the other hand, the control group will continue their Elderly Day Care Centre routine activities only",[28],[221,339,340,341,28],"Exercise","WhatsApp","Older Adults","2024-11-24",{"date":344,"type":33},"2024-11-27",{"date":346,"type":22},"2024-11-18",{"date":348,"type":22},"2025-01-31",{"name":350,"class":40},"International Islamic University Malaysia",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":17,"minAge":182,"maxAge":73,"enrollmentInfo":358,"targetDuration":4,"studyType":23,"phases":360,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":41},"100565363","intra-articular-dexmedetomidine-a-treatment-for-chronic-knee-pain-100565363","NCT06641206","Intra-Articular Dexmedetomidine: A Treatment for Chronic Knee Pain","Intra-articular Dexmedetomidine for Treatment of Chronic Knee Pain: A Prospective Case-Control Clinical Trial","Inclusion Criteria:\n\n* Patients were not assigned for surgical intervention;\n* Patients were free of exclusion criteria\n\nExclusion Criteria:\n\n* Patients were assigned for surgical intervention;\n* Patients who had uncontrolled hypertension and\u002For diabetes mellitus;\n* Patients who had uncompensated cardiac, renal, or hepatic diseases;\n* Patients with coagulopathy, spinal deformity, allergy, or contraindication for the used drugs;\n* Patients who refused to sign the informed consent were excluded from the study.",{"count":359,"type":22},70,[25],"Chronic knee osteoarthritis (KOA) is a painful condition with limited treatment options. Non-pharmacological approaches often fall short, leading to decreased quality of life. Ozone therapy, a simple and affordable treatment, has shown promise for pain relief. Dexmedetomidine (DEX), a sedative and analgesic, has been used successfully as an adjuvant to anesthesia and local anesthetics. Given its potential for pain management, exploring DEX as a treatment for KOA could offer a new and promising approach.",[28],"2024-10-11",{"date":365,"type":33},"2024-10-15",{"date":367,"type":33},"2024-09-17",{"date":369,"type":22},"2025-03",{"name":371,"class":40},"Tanta University",{"id":373,"slug":374,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":105,"enrollmentInfo":379,"targetDuration":4,"studyType":23,"phases":380,"briefSummary":381,"conditions":382,"keywords":384,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":393,"leadSponsor":395,"locationsCount":41},"100555643","sequential-genicular-nerve-ablation-prior-to-geniculate-artery-embolization-in-knee-pain-100555643","NCT06514755","Sequential Genicular Nerve Ablation Prior to Geniculate Artery Embolization in Knee Pain","Sequential Genicular Nerve Ablation Prior to Geniculate Artery Embolization in Knee Pain Management: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 to 80 years.\n* Diagnosed with chronic knee pain refractory to conservative treatment.\n* Able to provide informed consent.\n* Agree to follow the study procedures and attend follow-up visits.\n\nExclusion Criteria:\n\n* Contraindications to GNA or GAE procedures (e.g., allergy to local anesthetics, active infection at the procedure site).\n* Recent knee surgery within the last six months.\n* Severe comorbid conditions that may interfere with the study outcomes (e.g., rheumatoid arthritis, other severe autoimmune diseases).\n* Current participation in another clinical trial that could interfere with the outcomes of this study.",{"count":242,"type":22},[25],"The goal of this clinical trial is to evaluate whether performing genicular nerve ablation (GNA) before geniculate artery embolization (GAE) improves pain relief and knee function in patients with chronic knee pain. The main questions it aims to answer are:\n\n* Does performing GNA prior to GAE enhance pain relief, as measured by the Visual Analog Scale (VAS), at 3 months post-procedure?\n* Does the sequential approach improve knee function as assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)?\n\nStudy investigators will compare two groups to see if the sequential approach (GNA followed by GAE) provides better outcomes compared to GAE alone.\n\nParticipants will:\n\n* Undergo either sequential GNA followed by GAE or GAE alone\n* Have their knee pain and function assessed at baseline, 1 month, 3 months, and 6 months post-procedure\n* Complete a structured patient satisfaction questionnaire (PSQ) at 3 months post-procedure\n* Be monitored for procedure-related adverse events up to 6 months post-procedure,",[28,383],"Osteoarthritis",[385,386,387,388],"Genicular Nerve Ablation","Geniculate Artery Embolization","Knee Function","Patient Satisfaction","2024-09-29",{"date":391,"type":33},"2024-10-01",{"date":389,"type":33},{"date":394,"type":22},"2025-04-30",{"name":396,"class":397},"Zagazig University","OTHER_GOV",{"id":399,"slug":400,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":23,"phases":408,"briefSummary":409,"conditions":410,"keywords":413,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":5},"100470572","comparison-of-conventional-and-cooled-radiofrequency-of-the-genicular-nerves-in-patients-with-chronic-knee-pain-100470572","NCT05407610","Comparison of Conventional and Cooled Radiofrequency of the Genicular Nerves in Patients With Chronic Knee Pain","Comparison of Conventional and Cooled Radiofrequency Treatment of the Genicular Nerves Versus Sham Procedure for Patients With Chronic Knee Pain: a Multicentre, Double Blind, Randomised Controlled Trial","COGENIUS","Inclusion Criteria:\n\n* Signed written informed consent must be obtained before any study assessment is performed.\n* Adult patients (Age ≥ 18 years old).\n* Chronic anterior knee pain (\\> 12 months) that is moderate to severe (defined as NRS \\> 4 on most or all days for the index knee either constantly or with motion at time of screening and, an average NRS score reported in the patient diary \\>4 at the end of the run-in period).\n* Unresponsive (meaning insufficient pain reduction or intolerance) to conventional treatments ongoing for at least 12 months prior to inclusion. Conventional treatments must include all of the following: active physiotherapy, pharmacological treatment of pain and intra-articular corticosteroid infiltration.\n* Only for patients with Osteoarthritis (OA): Radiologic confirmation of knee osteoarthritis of grade 2 (mild), 3 (moderate) or 4 (severe) noted within 12 months prior to the screening for the index knee according the Kellgren Lawrence criteria diagnosed by an independent radiologist with experience in musculoskeletal imaging on radiography (Rx) or magnetic resonance imaging (MRI). If imaging will need to be performed at screening it is recommended to perform an MRI instead of Rx. Imaging with MRI will enable the independent radiologist to perform a better estimation of the grade of OA.\n* Only for patients with Persistent Post-Surgical Pain (PPSP) after Total Knee Arthroplasty (TKA): Patients with PPSP\\* after TKA need to have had a negative orthopaedic work-up\n\nExclusion Criteria:\n\n* Local or systemic infection (bacteraemia).\n* Evidence of inflammatory arthritis or an inflammatory systemic disease responsible for knee pain.\n* Intra-articular injections (steroids, hyaluronic acid, platelet enriched plasma, ...) in the index knee during the 3 months prior to procedure.\n* Pregnant, nursing or planning to become pregnant before the study intervention. Participants who become pregnant after the study intervention during the follow-up period will not be excluded.\n* Chronic widespread pain.\n* Patients with unstable psychosocial disorder.\n* Allergies to products used during the procedure (lidocaine, propofol, chlorhexidine).\n* Uncontrolled coagulopathy defined as supratherapeutic dose of anticoagulation medication.\n* Uncontrolled immune suppression.\n* Participating in another clinical trial\u002Finvestigation within 30 days prior to signing informed consent.\n* Patient is currently implanted with a neurostimulator.\n* Current radicular pain in index leg.\n* Previous conventional or cooled radiofrequency of the index knee.\n* Patients with bilateral knee pain defined as chronic knee pain (\\> 12 months) in both knees that is moderate to severe (defined as a numeric rating scale (NRS) \\> 4 on most or all days either constantly or with motion) and that is unresponsive (meaning insufficient pain reduction or intolerance) to conventional treatments ongoing for at least 12 months prior to inclusion. Conventional treatments must include all of the following: active physiotherapy, pharmacological treatment of pain and intra-articular corticosteroid infiltration.\n* Patients who have a planned TKA in the near future defined as patients who already have agreed on a date for the TKA procedure.\n* Patients who are unwilling or mentally incapable to complete the study questionnaires.",{"count":407,"type":22},400,[25],"Chronic knee pain remains a disabling disease despite current treatment strategies. There is an increase in the prevalence of osteoarthritis (OA) of the knee in the general population, presently affecting approximately 450,000 individuals in Belgium. A total knee replacement is a viable alternative for severe knee OA that does not respond to conservative therapy. Unfortunately, up to 53% of patients who undergo a total knee replacement develop persistent post-surgical pain (PPSP). There is currently no effective therapy for PPSP.\n\nA radiofrequency (RF) treatment applies high frequency current on the nerve responsible for pain conduction, resulting in an interruption of the transmission of pain. This can be applied to the nerves innervating the knee joint - the superolateral, superomedial and inferomedial genicular nerves - and could be an alternative, minimally invasive treatment for patients with knee OA who fail conservative treatments and for patients with PPSP. Data from the recent literature indicates that this treatment leads to a reduction of pain intensity and could result in an improvement of knee function, of the psychological state of the individual, and finally in an increase in health-related quality of life. Furthermore, RF of the genicular nerves could help avoid or delay a total knee replacement therefore potentially contributing to cost reduction. Both cooled and conventional RF treatments are reported in the literature to improve pain. The use of water to cool the RF electrodes results in an increased lesion size by removing heat from adjacent tissue, allowing power delivery to be increased. As a consequence, cooled RF could result in a higher chance of success and longer duration of effect. Until now, the studies performed on cooled RF are industry initiated and a direct comparison between conventional, cooled and a sham procedure is lacking.\n\nThe aim of the COGENIUS trial is to investigate the effect of the two types of RF treatment on individuals experiencing chronic knee pain that is resistant to conservative treatments. For this purpose, the efficacy and cost-effectiveness of cooled and conventional RF will be compared to a sham procedure in patients suffering from knee OA and PPSP after total knee replacement.",[411,412,28],"Knee Osteoarthritis","Persistent Postsurgical Pain",[383,412,414,415],"Knee","Radiofrequency ablation","2023-05-22",{"date":418,"type":33},"2023-05-24",{"date":420,"type":33},"2022-07-07",{"date":422,"type":22},"2026-09-01",{"name":424,"class":40},"Ziekenhuis Oost-Limburg"]